

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5949613

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
NADIA AHMAD	07/11/2018
RECEIVING PARTY DATA	
Name:	VERTEX PHARMACEUTICALS (EUROPE) LIMITED
Street Address:	2 KINGDOM STREET
City:	LONDON
State/Country:	UNITED KINGDOM
Postal Code:	W2 6BD
PROPERTY NUMBERS Total: 2	
Property Type	Number
Application Number:	16032799
PCT Number:	US2018041649
CORRESPONDENCE DATA	
Fax Number:	(734)489-8002
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	7344898004
Email:	docket-IN@btlaw.com, diane.schmidt@btlaw.com
Correspondent Name:	BARNES & THORNBURG LLP/JOSHUA NEY
Address Line 1:	2723 SOUTH STATE STREET
Address Line 2:	SUITE 150
Address Line 4:	ANN ARBOR, MICHIGAN 48104-6188
ATTORNEY DOCKET NUMBER:	67573.303693/303699
NAME OF SUBMITTER:	DIANE M. SCHMIDT
SIGNATURE:	/DIANE M SCHMIDT/
DATE SIGNED:	02/06/2020
Total Attachments: 4	
source=Nadia Ahmad signed assignment(15867075.1)#page1.tif	
source=Nadia Ahmad signed assignment(15867075.1)#page2.tif	
source=Nadia Ahmad signed assignment(15867075.1)#page4.tif	
source=Nadia Ahmad signed assignment(15867075.1)#page5.tif	

ASSIGNMENT

WHEREAS, Nadla Ahmad and David Shaw, the "Assignors", have made an invention entitled CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS, for a full description of which reference is here made to U.S. Provisional Application No. 62/531,313, filed July 11, 2017; U.S. Provisional Application No. 62/608,283, filed December 20, 2017; U.S. Patent Application No. 16/032,799, filed July 11, 2018; International Patent Application No. PCT/US2018/041649, filed July 11, 2018; Taiwanese Patent Application No. 107123989, filed July 11, 2018; Argentinian Patent Application No. 20180101925, filed July 11, 2018; Venezuelan Patent Application No. _____, filed July 11, 2018; and Uruguayan Patent Application No. 37806, filed July 11, 2018 (Note: I/We, the undersigned, hereby authorize the Assignee and/or its patent attorney(s) to fill in the application numbers of the foregoing patent applications when such application numbers become known to Assignee.);

WHEREAS, Vertex Pharmaceuticals (Europe) Limited, a company organized and existing under the laws of the United Kingdom and having an office and a place of business at 2 Kingdom Street, London, W2 6BD, United Kingdom, the "Assignee", desires to acquire the entire right, title and interest in the invention and the patent applications identified above, and all patents which may be obtained for the invention, as set forth below;

NOW, THEREFORE, in consideration of valuable and legally sufficient consideration, the receipt of which by the Assignors from the Assignee is acknowledged, the Assignors have sold, assigned and transferred, and by these presents hereby sell, assign and transfer to the Assignee, the entire right, title and interest for the United States in the invention and the patent applications identified above, and any patents that may issue for the invention in the United States; with the entire right, title and interest in the invention and all patent applications and patents issuing therefrom in all countries foreign to the United States, including the full right to claim for any such application all benefits and priority rights under any applicable

convention; with the entire right, title and interest in all continuations, divisions, reissues, reexaminations, renewals and extensions of any of the patent applications and patents defined above; with the right to recover all damages, including, but not limited to, a reasonable royalty, by reason of past, present, or future infringement or any other violation of patent or patent application rights; to have hold for the sole and exclusive use and benefit of the Assignee, its successors and assigns, to the full end of the term or terms for all such patents.

The Assignors covenant and agree, for both the Assignors and the Assignors' legal representatives, that the Assignors will assist the Assignee in the prosecution of the patent applications identified above; in the making and prosecution of any other patent applications that the Assignee may elect to make covering the invention identified above; in vesting in the Assignee exclusive title in all such other patent applications and patents; and that the Assignors will execute and deliver to the Assignee all additional papers which may be requested by the Assignee to carry out the terms of this Assignment.

The Commissioner of Patents and Trademarks is authorized and requested to issue patents to the Assignee under the terms of this Assignment.

IN TESTIMONY WHEREOF, the Assignors have executed this agreement.

DATED: _____

David Shaw

IN WITNESS WHEREOF, I have hereunto set hand and seal

Signature of witness: (1) _____

Printed Name of Witness: _____

this _____ day of _____
Date of signing

Signature of witness: (2) _____

Printed Name of Witness: _____

this _____ day of _____
Date of signing

ACKNOWLEDGMENT OF ASSIGNEE

By: Kerry A. Flynn
Kerry A. Flynn
Vice President and Chief IP Counsel
on behalf of Vertex Pharmaceuticals (Europe) Limited

Date: July 11, 2018

Commonwealth of Massachusetts
County of Suffolk

On this 11th day of July, 2018, before me, the undersigned notary public, personally appeared Kerry A. Flynn, proved to me through satisfactory evidence of identification which was/were: personal knowledge of identity, a driver's license, other (please identify) _____, to be the person whose name is signed on this document, and who swore or affirmed to me that the contents of the document are truthful and accurate to the best of his/her knowledge and belief.

Lauren M. DeVincenzo
Notary Public
My Commission Expires: Dec 23, 2022

